drugset / Trial / NCT07398560

Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study

NCT07398560 ↗

Phase 2 Not yet recruiting 47 enrolled The Third Affiliated Hospital of Harbin Medical University
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, single-arm, exploratory clinical study designed to observe and evaluate the efficacy and safety of adebrelimab combined with oral etoposide for elderly patients and patients with poor performance status in small cell lung cancer.

Timeline

Start
2026-02-01
Primary completion
2028-02-01
Completion
2029-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 1200 mg Intravenous
Subject Etoposide Small molecule 75 mg Oral